Developing Viral Vectors for Lymphoid and Myeloid Cell Therapy
Research type
Research Study
Full title
Developing Next Generation Viral Vectors for Lymphoid and Myeloid Cell and Gene Therapy
IRAS ID
338668
Contact name
Qian Liu
Contact email
Sponsor organisation
OXGENE/Oxford Genetics Ltd
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
Gene therapy, where exogenous DNA sequences are delivered by modified viruses (viral vectors) to create therapeutically modified cells, is a promising strategy for the treatment of diseases of the immune system. This research project seeks to deliver next generation viral vectors with substantially improved immune cell gene therapy capabilities, through engineering and assessment of viral vector components.
We propose to purify cells of the lymphoid and myeloid lineages from human blood samples. These cells will then be modified by introduction of DNA using lentivirus (LV) or adeno-associated virus (AAV) assisted gene transfer (non-viral DNA transfer methods may be used for comparative purposes). A range of in vitro assays will be used to assess the properties of the resulting cells. The data produced in these assays will allow the identification improved viral vectors.
As part of this application, we would also like to request permission to continue to store samples from our current REC-approved project (REC reference: 21/NW/0202, IRAS project ID: 291740) for use in this newly proposed project. These samples are peripheral blood mononuclear cells (PBMCs) and T cells purified from donor blood and cryopreserved. Use of these samples will prevent the waste of donor material and reduce the number of donors required for the proposed project.
REC name
London - South East Research Ethics Committee
REC reference
24/PR/0082
Date of REC Opinion
13 Feb 2024
REC opinion
Further Information Favourable Opinion